Armata Pharmaceuticals, Inc. - 8-K Filing
Armata Pharmaceuticals reports Q3 2026 net income of $54.9 million driven by a $69.6 million fair value gain on convertible loan. (Items: 2.02 and the attached Exhibit 99)
Tickers: $ARMP
More Regulatory news
- FACT II Acquisition Corp. - 10-Q Filing
- Marblegate Capital Corp - 10-Q Filing
- Greenland Mines Ltd - 8-K Filing
- InspireMD, Inc. - 8-K Filing
- InspireMD, Inc. - 8-K Filing
- Pinnacle Acquisition Corp - 10-Q Filing
- SUTRO BIOPHARMA, INC. - 8-K Filing
- Aeluma, Inc. - 8-K Filing
- ASTEC INDUSTRIES INC - 8-K Filing
- Live Oak Bancshares, Inc. - 8-K Filing